baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out SNW/ DE000UK6XPA8 /

2024-06-14 6:01:23 PM	Chg.-0.180	Bid6:01:23 PM	Ask6:01:23 PM	Underlying	Strike price	Expiration date	Option type
4.750EUR	-3.65%	4.750 Bid Size: 500	4.810 Ask Size: 500	SANOFI SA INHABER ...	39.1638 EUR	2078-12-31	Call

GlobeNewswire 06-11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 06-03 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...

GlobeNewswire 05-31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 05-30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewswire 05-27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...

GlobeNewswire 05-23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...

GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months

TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal

GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...

GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

TeleTrader 05-09 Europe opens mixed with BoE in focus

GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

UBS Knock-Out SNW/ DE000UK6XPA8 /

If you wish to receive reply to your feedback, please provide your email address.